title: Colistimethate sodium therapy for multidrug-resistant isolates in pediatric patients.
abstract: OBJECTIVE
  The aim of the present study was to assess the efficacy and safety of colistimethate sodium therapy in multidrug-resistant nosocomial infections caused by Pseudomonas aeruginosa or Acinetobacter baumannii in neonates and children.
  
  
  METHODS
  Pediatric patients hospitalized at the Uludag University Hospital who had nosocomial infections caused by multidrug-resistant P. aeruginosa or A. baumannii, were enrolled in the study. Colistimethate sodium at a dosage of 50-75 x 10(3) U/kg per day was given i.v. divided into three doses.
  
  
  RESULTS
  Fifteen patients received 17 courses of colistimethate sodium for the following infections: ventilator-associated pneumonia (n= 14), catheter-related sepsis (n= 1) and skin and soft-tissue infection (n= 2). The mean age of patients was 53.2 + 74.7 months (range, 8 days-15 years) and 60% were male. Mortality was 26.6%.
  
  
  CONCLUSIONS
  Colistimethate sodium appears to be safe and effective for the treatment of severe infections caused by multidrug-resistant P. aeruginosa or A. baumannii in pediatric patients.
authors.affiliation: Uludag University Medical Faculty, Department of Pediatrics, Division of Pediatric Infectious Diseases, Gorukle, Bursa, Turkey. solmaz@uludag.edu.tr
authors.forename: Solmaz
authors.initials: S
authors.lastname: Celebi
authors.forename: Mustafa
authors.initials: M
authors.lastname: Hacimustafaoglu
authors.forename: Nilgun
authors.initials: N
authors.lastname: Koksal
authors.forename: Hilal
authors.initials: H
authors.lastname: Ozkan
authors.forename: Merih
authors.initials: M
authors.lastname: Cetinkaya
mesh_terms: D000151:Acinetobacter Infections / Q000175:diagnosis / Q000188:drug therapy*; D040981:Acinetobacter baumannii / Q000187:drug effects / Q000302:isolation & purification; D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D003091:Colistin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D003428:Cross Infection / Q000188:drug therapy* / Q000382:microbiology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D024901:Drug Resistance, Multiple, Bacterial; D005260:Female; D005500:Follow-Up Studies; D006785:Hospitals, University; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007275:Injections, Intravenous; D007363:Intensive Care Units, Neonatal; D015278:Intensive Care Units, Pediatric; D008297:Male; D008826:Microbial Sensitivity Tests; D011446:Prospective Studies; D011552:Pseudomonas Infections / Q000175:diagnosis / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D014421:Turkey
chemical_list: C004691:colistinmethanesulfonic acid; D003091:Colistin